

ASX RELEASE

2 December 2020

Amplia Receives \$0.53m R&D Tax Incentive

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) wishes to advise that it has received a Research and Development Tax Incentive Refund of \$533,521 for the 2019/2020 financial year. The refund recognizes expenditure primarily incurred in the manufacture and toxicology studies of the Company’s clinical-stage FAK inhibitor, AMP945. These R&D activities underpinned the initiation of the Company’s ongoing Phase 1 clinical trial of AMP945 in healthy volunteers.

The Australian Government’s Research and Development Tax Incentive Refund provides companies with cash refunds for 43.5% of eligible expenditure on research and development activities.

This ASX announcement has been approved and authorised by the Board of Amplia Therapeutics.

- End -

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company (ASX:ATX) advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer therapy and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF).

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com